Flavonoid apigenin modified gene expression associated with inflammation and cancer and induced apoptosis in human pancreatic cancer cells through inhibition of GSK-3β/NF-κB signaling cascade

Molecular Nutrition and Food Research

Volumn 57, Issue 12, 2013, Pages 2112-2127

  Johnson, Jodee L ^a   De Mejia, Elvira Gonzalez ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Apigenin; Flavonoids; GSK 3 ; NF B; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; APIGENIN; ASCORBIC ACID; CYTOKINE; FLAVONOID; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CHEMISTRY; CITRUS; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVE SITE; GENE EXPRESSION REGULATION; GENETICS; GSK-3Β; HUMAN; INFLAMMATION; METABOLISM; NF-ΚB; PANCREAS CANCER; PANCREAS TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APIGENIN; FLAVONOIDS; GSK-3Β; NF-ΚB; PANCREATIC CANCER;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APIGENIN; APOPTOSIS; ASCORBIC ACID; CATALYTIC DOMAIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CITRUS; CYTOKINES; DRUG SCREENING ASSAYS, ANTITUMOR; FLAVONOIDS; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INFLAMMATION; NF-KAPPA B; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84881495790     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201300307     Document Type: Article

References (52)

1. Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63, 11-30.
2. Hingorani, S. R., in: Lowy, A. M., Philip, P. A., Leach, S. D., Pollock, R. E. (Eds.), Pancreatic Cancer, Springer Science+Business Media, LLC, New York 2008, pp.159-180.
3. Vaccaro, V., Melisi, D., Bria, E., Cuppone, F. et al., Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Expert Opin. Ther. Tar. 2011, 15, 1183-1196.
4. Luo, J., Glycogen synthase kinase 3β (GSK3β) in tumorigenesis and cancer chemotherapy. Cancer Lett. 2009, 273, 194-200.
5. Kitano, A., Shimasaki, T., Chikano, Y., Nakada, M. et al., Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy. PLoS One 2013, 8, 1-12.
6. Ban, J. O., Kwak, D. H., Oh, J. H., Park, E. et al., Suppression NF-κB and GSK-3β is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. Chem. Biol. Interact. 2010, 188, 75-85.
7. Hillard, T. S., Gaisina, I. N., Muehlbauer, A. G., Gaisin, A. M. et al., Glycogen synthase kinase-3β inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth. Anticancer Drug. 2011, 22, 978-985.
8. Zhang, J., Koenig, A., Harrison, A., Ugolkov, A. V. et al., Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer. Oncogene 2011, 30, 3705-3715.
9. Ougolkov, A. V., Fernandez-Zapico, M. E., Savoy, D. N., Urritia, R. A. et al., Glycogen synthase kinase-3β participates in nuclear factor κB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. 2005, 65, 2076-2081.
10. Ougolkov, A. V., Fernandez-Zapico, M. E., Bilim, V. N., Smyrk, T. C. et al., Aberrant nuclear accumulation of glycogen synthase kinase-3β in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin. Cancer Res. 2006, 12, 5074-5081.
11. Wilson III, W., Baldwin, A. S., Maintenance of constitutive IκB kinase activity by glycogen synthase kinase-3α/β in pancreatic cancer. Cancer Res. 2008, 68, 8156-8163.
12. Mamaghani, S., Patel, S., Hedley, D. W., Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. BMC Cancer 2009, 9, 132. doi:10.1186/1471-2407-9-132.
13. Holcomb, B., Yip-Schneider, M., Schmidt, C. M., The role of nuclear factor κB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas 2009, 36, 225-235.
14. Giroux, V., Dagorn, J. C., Iovanna, J. L., A review of kinases implicated in pancreatic cancer. Pancreatology 2009, 9, 738-754.
15. Bae, J., Lee, E. J., Guyatt, G., Citrus fruit intake and pancreatic cancer risk. Pancreas 2009, 38, 168-174.
16. Polesel, J., Talamini, R., Negri, E., Bosetti, C. et al., Dietary habits and risk of pancreatic cancer: an Italian case-control study. Cancer Causes Control 2010, 21, 493-500.
17. Jansen, R. J., Robinson, D. P., Stolzenberg-Solomon, R. Z., Bamlet, W. R. et al., Fruit and vegetable consumption is inversely associated with having pancreatic cancer. Cancer Causes Control 2011, 22, 1613-1625.
18. Patil, J. R., Chidambara Murthy, K. N., Jayaprakasha, G. K., Chetti, M. B. et al., Bioactive compounds from Mexican lime (Citrus aurantifolia) juice induce apoptosis in human pancreatic cells. J. Agric. Food Chem. 2009, 57, 10933-10942.
19. Patil, J. R., Jayaprakasha, G. K., Chidambara Murthy, K. N., Chetti, M. B. et al., Characterization of Citrus aurantifolia bioactive compounds and their inhibition of human pancreatic cancer cells through apoptosis. Microchem. J. 2010, 94, 108-117.
20. Chidambara Murthy, K. N., Jayaprakasha, G. K., Patil, B. S., Apoptosis mediated cytotoxicity of citrus obacunone in human pancreatic cancer cells. Toxicol. In Vitro 2011, 25, 859-867.
21. Shukla, S., Gupta, S., Apigenin: a promising molecule for cancer prevention. Pharm. Res. 2010, 27, 962-978.
22. Tahanian, E., Sanchez, L. A., Shiao, T. C., Roy, R. et al., Flavonoids targeting of IκB phosphorylation abrogates carcinogen-induced MMP-9 and COX-2 expression in human brain endothelial cells. Drug Des. Dev. Ther. 2011, 5, 299-309.
23. Turktekin, M., Konac, E., Onen, H. I., Alp, E. et al., Evaluation of the effects of the flavonoid apigenin on apoptotic pathway gene expression on the colon cancer cell line (HT29). J. Med. Food 2011, 14, 1107-1117.
24. King, J. C., Lu, Q., Li, G., Mora, A. et al., Evidence for activation of mutated p53 by apigenin in human pancreatic cancer. Biochim. Biophys. Acta 2012, 1823, 593-604.
25. Berrozpe, G., Schaeffer, J., Peinado, M. A., Real, F. X. et al., Comparative analysis of mutations in the p53 and K-Ras genes in pancreatic cancer. Int. J. Cancer 1994, 58, 185-191.
26. Naumann, M., Savitskaia, N., Eilert, C., Schramm, A. et al., Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations of p16/MTS1 in pancreatic tumors. Gastroenterology 1996, 110, 1215-1224.
27. Hahn, S. A., Schutte, M., Hoque, A. T., Moskaluk, C. A. et al., DPCA, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996, 271, 350-353.
28. Moore, P. S., Sipos, B., Orlandini, S., Sorio, C. et al., Genetic profile of 22 pancreatic carcinoma cell lines, analysis of K-Ras, p53, p16 and DPC4/Smad4. Virchows Arch. 2001, 439, 798-802.
29. Furukawa, T., Duguid, W. P., Rosenberg, L., Viallet, J. et al., Long term culture and immortalization of epithelial cells from normal adult human pancreatic ducts by transfection with the E6E7 gene of human papilloma virus 16. Am. J. Pathol. 1996, 148, 1763-1770.
30. Ouyang, H., Mou, L-J., Luk, C., Liu, N. et al., Paradiploid human pancreatic duct epithelial cell lines with near normal phenotype. Am. J. Pathol. 2000, 157, 1623-1631.
31. Dia, V. P., Gonzalez de Mejia, E., Lunasin induces apoptosis and modifies the expression of genes associated with extracellular matrix and cell adhesion in human metastatic colon cancer cells. Mol. Nutr. Food Res. 2011, 55, 623-634.
32. Johnson, J. L., Rupasinghe, S. G., Stefani, F., Shuler, M. A. et al., Citrus flavonoids luteolin, apigenin, and quercetin inhibit glycogen synthase kinase-3β enzymatic activity by lowering the interaction energy within the binding cavity. J. Med. Food. 2011, 14, 325-333.
33. Norbury, C., Nurse, P., Animal cell cycles and their control. Annu. Rev. Biochem. 1992, 161, 441-470.
34. Ujiki, M. B., Ding, X., Salabat, M. R., Bentrem et al., Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol. Cancer. 2006, 5, 76. doi:10.1186/1476-4598-5-76.
35. Hamacher, R., Schmid, R. M., Saur, D., Schneider, G., Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol. Cancer. 2008, 7, 64. doi:10.1186/1476-4598-7-64.
36. Moseley, T. A., Haudenschild, D. R., Rose, L., Reddi, A. H., Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003, 14, 155-174.
37. Martin-Orozco, N., Muranski, P., Chung, Y., Yang, X. O. et al., T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009, 31, 787-798.
38. Li, Y., Cao, Z. Y., Sun, B., Wang, G. Y. et al., Effects of IL-17A on the occurrence of lung adenocarcinoma. Cancer Biol. Ther. 2011, 12, 610-616.
39. Tong, Z., Yang, X. O., Yan, H., Liu, W. et al., A protective role by interleukin-17F in colon tumorigenesis. PLoS One, 2012, 7. doi:10.1371/journal.pone0034954.
40. Chae, W., Bothwell, A. L. M., IL-17F deficiency inhibits small intestinal tumorigenesis in ApcMin/+ mice. Biochem. Biophys. Res. Comm. 2011, 414, 31-36.
41. Benetar, T., Cao, M. Y., Lee, Y., Lightfoot, J. et al., IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo. Cancer Immunol. Immun. 2010, 59, 805-817.
42. Gnerlich, J. L., Mitchem, J. B., Weir, J. S., Sankpal, N. V. et al., Induction of Th17 cells in tumor microenvironment improves survival in a murine model of pancreatic cancer. J. Immunol. 2010, 185, 4063-4071.
43. Fahrig, R., Quietzch, D., Heinrich, J., Heinemann, V. et al., RP101 improves the efficacy of chemotherapy in pancreas carcinoma cell lines and pancreatic cancer patients. Anticancer Drug. 2006, 17, 1045-1056.
44. Vitale, G., van Eijck, C. H. J., van KoetsveldIng, P. M., Erdmann, J. I. et al., Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann. Surg. 2007, 246, 259-268.
45. Ravet, E., Lulka, H., Gross, F., Casteilla, L. et al., Using lentiviral vectors for efficient pancreatic cancer gene therapy. Cancer Gene Ther. 2010, 17, 315-324.
46. Wang, H., Brown, J., Garcia, C. A., Tang, Y. et al., The role of glycogen synthase kinase 3 in regulating IFN-β-mediated IL-10 production. J. Immunol. 2011, 186, 675-684.
47. Huang, F., Kao, C., Wachi, S., Thai, P. et al., Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-κB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells. J. Immunol. 2007, 179, 6504-6513.
48. Shen, F., Li, N., Gade, P., Kalvakolanu, D. V. et al., IL-17 receptor signaling inhibits C/EBPβ by sequential phosphorylation of the regulatory 2 domain. Sci. Signal. 2009, 2. doi:10.1126/scisignal.2000066.
49. Rao, P. S., Satelli, A., Moridani, M., Jenkins, M. et al., Luteolin induces apoptosis in multidrug resistant cancer cells without affecting the drug transporter function: involvement of cell line-specific apoptotic mechanisms. Int. J. Cancer 2012, 130, 2703-2714.
50. Meyer, H., Bolarinwa, A., Wolfram, G., Linseisen, J., Bioavailability of apigenin from apiin-rich parsley in humans. Ann. Nutr. Metab. 2006, 50, 167-172.
51. Yallapu, M. M., Jaggi, M., Chauhan, S. C., Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov. 2012, 17, 71-80.
52. Clark, A., Labute, P., 2D depiction of protein-ligand complexes. J. Chem. Inf. Model. 2007, 47, 1933-1944.